Hudson Capital Management LLC Purchases 357 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hudson Capital Management LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,961 shares of the biopharmaceutical company’s stock after acquiring an additional 357 shares during the quarter. Hudson Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,534,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. AE Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 19.4% during the second quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 89 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. Sei Investments Co. now owns 24,944 shares of the biopharmaceutical company’s stock valued at $26,214,000 after acquiring an additional 537 shares during the last quarter. Gabelli Funds LLC grew its stake in Regeneron Pharmaceuticals by 1.8% during the 2nd quarter. Gabelli Funds LLC now owns 1,893 shares of the biopharmaceutical company’s stock worth $1,990,000 after buying an additional 34 shares during the last quarter. Public Sector Pension Investment Board lifted its position in Regeneron Pharmaceuticals by 77.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 3,841 shares of the biopharmaceutical company’s stock worth $4,037,000 after acquiring an additional 1,679 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in Regeneron Pharmaceuticals by 61.1% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 20,674 shares of the biopharmaceutical company’s stock worth $21,729,000 after acquiring an additional 7,840 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $680.03 on Thursday. The firm’s 50-day simple moving average is $733.06 and its two-hundred day simple moving average is $943.95. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $74.73 billion, a price-to-earnings ratio of 16.83, a P/E/G ratio of 1.62 and a beta of 0.10.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Citigroup lowered their price objective on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.